Meta Information
ID:menopausal-hrt
Name:
Schema Version:AIM-2.0
Interactions
Target id:
/class/broad-spectrum-inducers
Target name:
Broad-Spectrum Metabolic Enzyme Inducers
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Description:
Certain medications (like some anticonvulsants and antibiotics like rifampin) strongly increase the activity of liver enzymes (CYP3A4) that break down estrogens and progestins, significantly lowering HRT levels and reducing its effectiveness.
Actionable advice:
Avoid this combination; if necessary, your HRT dose may need to be significantly increased and monitored.
Target id:
/intervention/saint-johns-wort
Target name:
Saint John's Wort
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Description:
St. John's Wort is a potent inducer of the CYP3A4 enzyme, which metabolizes the hormones in HRT, leading to lower hormone levels and potential loss of symptom control.
Actionable advice:
Avoid taking St. John's Wort while on menopausal HRT.
Target id:
/class/cyp3a4-strong-inhibitors
Target name:
Strong CYP3A4 Inhibitors
Severity:
major
Interaction type:
adverse
Nature:
absolute
Description:
Strong inhibitors of the CYP3A4 enzyme (e.g., ketoconazole, clarithromycin, ritonavir) block the breakdown of HRT hormones, leading to elevated levels and an increased risk of side effects like blood clots and breast tenderness.
Actionable advice:
Avoid this combination; if unavoidable, a lower dose of HRT and close monitoring are required.
Target id:
/dietary/grapefruit-pomelo
Target name:
Grapefruit and Grapefruit Juice
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Description:
Grapefruit contains compounds that inhibit the CYP3A4 enzyme in the gut and liver, which can increase the absorption and levels of oral estrogens, raising the risk of side effects.
Actionable advice:
Avoid regular consumption of grapefruit or grapefruit juice when taking oral HRT.
Target id:
/intervention/levothyroxine_systemic_disease
Target name:
Levothyroxine
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Description:
Oral estrogens increase levels of thyroid-binding globulin (TBG), a protein that binds to thyroid hormone, which can decrease the amount of free, active thyroid hormone available. This interaction is less significant with transdermal HRT.
Actionable advice:
If you take thyroid medication, your dose may need to be adjusted after starting oral HRT; regular thyroid function monitoring is essential.
Target id:
/intervention/lamotrigine
Target name:
Lamotrigine
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Description:
Oral estrogen-containing HRT can significantly increase the clearance of lamotrigine, substantially lowering its blood levels and potentially leading to a loss of seizure control or mood stabilization.
Actionable advice:
Avoid combining oral HRT with lamotrigine; if necessary, expect significant lamotrigine dose adjustments and close monitoring.
Target id:
/condition/history-hormone-sensitive-cancer
Target name:
History of Breast or Endometrial Cancer
Severity:
major
Interaction type:
adverse
Nature:
absolute
Description:
Menopausal HRT is contraindicated in individuals with a current or past history of estrogen-sensitive cancers, as it may promote cancer recurrence or growth.
Actionable advice:
Do not use menopausal HRT if you have a history of breast, uterine, or other hormone-sensitive cancers.
Target id:
/condition/active-vte
Target name:
Active or History of VTE/DVT/PE
Severity:
major
Interaction type:
adverse
Nature:
absolute
Description:
Estrogen increases the risk of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). It is contraindicated in those with an active clot or a high-risk history.
Actionable advice:
Do not use menopausal HRT if you have a current blood clot or a history of clots related to estrogen use.
Target id:
/condition/smoking
Target name:
Smoking
Severity:
major
Interaction type:
adverse
Nature:
absolute
Description:
Smoking significantly amplifies the risk of serious cardiovascular events, such as blood clots, heart attack, and stroke, when combined with systemic HRT, particularly in women over 35.
Actionable advice:
It is strongly recommended to stop smoking before starting and while using menopausal HRT.
Target id:
/condition/hepatic-impairment
Target name:
Severe Liver Disease
Severity:
major
Interaction type:
adverse
Nature:
absolute
Description:
The liver is the primary site of hormone metabolism. In cases of severe liver dysfunction, hormone clearance is impaired, leading to accumulation and increased risk, making HRT contraindicated.
Actionable advice:
Do not use menopausal HRT if you have active or severe liver disease.
Target id:
/condition/unexplained-vaginal-bleeding
Target name:
Unexplained Vaginal Bleeding
Severity:
major
Interaction type:
adverse
Nature:
absolute
Description:
Unexplained vaginal bleeding must be diagnosed before starting HRT, as it could be a sign of an underlying condition, such as endometrial hyperplasia or cancer, which would be worsened by HRT.
Actionable advice:
Ensure any abnormal vaginal bleeding is fully investigated by a doctor before considering HRT.
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Description:
Menopausal HRT is not a form of contraception and is contraindicated during pregnancy due to potential harm to the developing fetus.
Actionable advice:
Do not use menopausal HRT if you are pregnant or may become pregnant.
Target id:
/class/bile-acid-sequestrants
Target name:
Bile Acid Sequestrants
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
4
Hours after target:
4
Description:
Bile acid sequestrants (e.g., cholestyramine) can bind to oral estrogens in the intestine, preventing their absorption and reducing the effectiveness of HRT.
Actionable advice:
Take oral HRT at least 4 hours before or 4 hours after taking a bile acid sequestrant.
Target id:
/class/aromatase-inhibitors
Target name:
Aromatase Inhibitors
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Description:
Aromatase inhibitors (e.g., anastrozole, letrozole) work by blocking estrogen production and are used to treat hormone-sensitive breast cancer. Taking estrogen-containing HRT directly counteracts their therapeutic purpose.
Actionable advice:
Do not take menopausal HRT concurrently with aromatase inhibitors.
Target id:
/class/selective-estrogen-receptor-modulators
Target name:
Selective Estrogen Receptor Modulators (SERMs)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Description:
SERMs (e.g., tamoxifen, raloxifene) and estrogens compete for the same receptors. Using them together can lead to unpredictable effects and is not recommended.
Actionable advice:
Do not use menopausal HRT at the same time as a SERM.
Target id:
/class/corticosteroids
Target name:
Corticosteroids
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Description:
Estrogens can inhibit the metabolism of corticosteroids, potentially increasing their levels and effects, which may require a dose adjustment of the corticosteroid.
Actionable advice:
Be aware that your corticosteroid dose may need to be lowered; monitor for increased side effects.
Target id:
/dietary/alcohol-acute
Target name:
Alcohol
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Description:
Regular alcohol consumption can increase circulating estrogen levels, which may heighten the long-term risks associated with HRT, such as breast cancer.
Actionable advice:
Limit alcohol intake while on menopausal HRT to minimize potential long-term risks.
Target id:
/biomarker/thyroid-panel
Target name:
Thyroid Panel
Severity:
moderate
Interaction type:
assay_interference
Nature:
absolute
Description:
Oral estrogen increases thyroid-binding globulin (TBG), which can lead to an artificially high Total T4 and Total T3 reading. Free T4 and TSH levels are more reliable indicators of thyroid status.
Actionable advice:
Inform your doctor you are on oral HRT when interpreting thyroid tests; rely on Free T4 and TSH for accuracy.
Target id:
/biomarker/lipid-panel
Target name:
Lipid Panel
Severity:
minor
Interaction type:
assay_interference
Nature:
absolute
Description:
HRT can alter lipid profiles, typically by lowering LDL ('bad') cholesterol and raising HDL ('good') cholesterol, but oral estrogens may also increase triglycerides.
Actionable advice:
Be aware that HRT will affect your lipid panel results; monitor triglycerides, especially with oral formulations.
Target id:
/dietary/meal
Target name:
Any Caloric Meal
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Description:
Taking oral HRT with food does not significantly impact overall absorption but can help minimize gastrointestinal side effects such as nausea.
Actionable advice:
Take oral HRT with food if you experience stomach upset, and be consistent with your timing relative to meals.
Target id:
/procedure/topical-application-site-rotation
Target name:
Transdermal HRT Application Site Rotation
Severity:
moderate
Interaction type:
requirement
Nature:
absolute
Description:
Consistent application of transdermal HRT (patches, gels) to the same area of skin can cause irritation and may lead to inconsistent hormone absorption over time.
Actionable advice:
Rotate the application site for transdermal HRT with each new dose as instructed by the product labeling.
Target id:
/intervention/sunscreen
Target name:
Sunscreen and Other Lotions
Severity:
minor
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
1
Hours after target:
1
Description:
Applying sunscreen or other lotions to the skin shortly before or after applying transdermal HRT gel can interfere with its absorption through the skin.
Actionable advice:
Wait at least one hour after applying HRT gel before applying sunscreen or lotion to the same area.